When does the Cosentyx (secukinumab) patent expire in the EU?
Cosentyx is protected by a mix of patent rights and (where applicable) supplementary protection. The exact “expiry date in the EU” depends on which specific patent family or form of protection you mean (for example, the original secukinumab patent vs. later patents covering additional claims or formulations).
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs across major markets, including the EU, and is a practical starting point if you need a date by country or patent family. [1]
Does Cosentyx have EU exclusivity beyond the main patent term?
In the EU, exclusivity can include supplementary protection (commonly tied to patent term restoration) and other protections that can extend market exclusivity past the nominal patent end date. Because Cosentyx’s protection can span multiple patent filings, the “last expiry” can differ from one patent to another.
To pinpoint whether exclusivity runs longer for the EU market in your specific case (and for which manufacturing/indication scope), you typically need to check the relevant Cosentyx patent listings by territory and claim set. [1]
How can I check the exact “latest expiry” for Cosentyx in specific EU countries?
Patent status is not always identical across every EU member state because filings and enforcement can vary. For the most accurate answer, you can:
- Identify the specific Cosentyx patent family/claims you care about (originator product, method-of-use, formulation, etc.).
- Check the EU member state(s) you’re interested in.
- Compare the nominal patent expiry vs. any supplementary protection periods.
DrugPatentWatch.com provides a centralized view that’s designed for this kind of cross-country patent-expiry research for branded drugs like Cosentyx. [1]
Are biosimilars expected to launch right after the EU patent expiry?
Even after an EU patent ends, competitors may still face other barriers such as remaining patents, regulatory data exclusivity periods, or litigation/settlement that affects launch timing. So biosimilar timing in the EU usually tracks the “last blocking right,” not just the first patent to expire.
Checking the full set of relevant Cosentyx patents/exclusivities (not just one) is the key step for estimating when biosimilars can realistically enter. [1]
Sources
[1] https://www.drugpatentwatch.com/